期刊： JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022; 27 ()
Background: Little data is published describing the use of medications prescribed for pulmonary arterial hypertension (PAH) in patients receiving extr......
期刊： JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022; 27 ()
Peripheral artery disease (PAD) is a severe manifestation of atherosclerosis. Patients with PAD are at heightened risk for atherothrombotic complicati......
期刊： JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022; 27 ()
Background: Because of logistic challenges associated with the COVID-19 pandemic, direct oral anticoagulants (DOAC) were favored over warfarin in pati......
期刊： JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022; 27 ()
Our paper highlights the past 50 years of research focusing solely on tolerance involving nitroglycerin (glyceryl trinitrate, GTN). It also identifies......
期刊： JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022; 27 ()
Remote ischemic conditioning (RIC) induces the release of circulating cardioprotective factors and attenuates myocardial ischemia/reperfusion injury. ......
期刊： JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022; 27 ()
Medical therapy for secondary prevention is known to be under-used in patients with peripheral artery disease (PAD). Few data are available on the sub......
期刊： JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022; 27 ()
Background and Aims: Morphine use for patients presenting with NSTE-ACS is associated with excess mortality. However, the role of morphine in STE-ACS ......
期刊： JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022; 27 ()
Evidence suggests that interruption of beta-blockers during acute decompensated heart failure (ADHF) in the absence of contraindications leads to poor......
期刊： JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022; 27 ()
Aim: This retrospective cohort study aimed to evaluate the prognostic implications of the distinct atrial fibrillation (AF) temporal patterns: first d......
期刊： JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022; 27 ()
Purpose: Interest in improving residual cardiovascular (CV) risk by targeting multiple causative pathways has been growing. Several medications includ......
期刊： JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022; 27 ()
Background: Pulmonary hypertension (PHT) is common in beta-thalassemia patients due to hemolysis, iron overload and diminished nitric oxide (NO) level......
期刊： JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022; 27 ()
Introduction: Studies suggest that non-alcoholic fatty liver disease (NAFLD) is associated with an independent risk of cardiovascular disease (CVD). W......
期刊： JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022; 27 ()
Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibit......
期刊： JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022; 27 ()
Objective: The purpose of this study was to determine the impact of varying inflation parameters on paclitaxel delivery and retention using a commerci......
期刊： JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022; 27 ()
Purpose: Low plasma concentrations of the amino acid homoarginine (HA) have been shown to correlate with adverse cardiovascular outcome, particularly ......
